·
The idea that Botox (botulinum toxin A) could help with
depression is
being explored by, Allergan, despite the latest
trial showing patchy results.
Based on the “facial feedback” hypothesis, which holds that
facial
movement can influence emotional experience,
Allegan is hopeful the drug’s
anti-wrinkle and anti-frowning
formula can be used to improve mood.
Anecdotal evidence suggests Botox is already used off-label
for this
purpose.
Yet results from a phase II study of almost 260 patients show
that Botox is unable to meaningfully reduce depression after
six weeks compared
with placebo.
A 30-unit dose of Botox appears to be better at reducing
depression than
placebo, but the results are clinically
insignificant.
The study also suggests that less is more, with a stronger 50-
unit dose
of the drug showing no benefit compared with the
placebo.
Nonetheless, Allergan says it will press ahead with phase III.
“We are encouraged by these data and the potential impact
on adults with
major deperssive disorder,” says David
Nicholson, Allergan’s chief research and
development officer.
“Given our in-depth and extensive clinical trial experience in
the
central nervous system, including depression, we plan to
move forward and
develop a phase III program for a
potential new treatment option for patients.”
Commenti
Posta un commento